Pfizer Inc.’s XALKORI® Receives Conditional Marketing Authorization From the European Commission (EC) for the Treatment of Adults With Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission has given conditional marketing authorization for XALKORI® (crizotinib) in the European Union (EU) for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).